• Molecular NameSirolimus
  • SynonymAntibiotic AY 22989; rapamycin; sirolimus
  • Weight914.187
  • Drugbank_IDDB00877
  • ACS_NO53123-88-9
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)7.84
  • pkaN/A
  • LogD (pH=7, predicted)7.83
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.15
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.65
  • No.of HBond Donors3
  • No.of HBond Acceptors14
  • No.of Rotatable Bonds6
  • TPSA195.43
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability15.0
  • Protein binding92.0
  • Volume of distribution (VD)12 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmSirolimus is metabolized primarily by CYP3A and is a substrate for P-glycoprotein. Several sirolimus metabolites are pharmacologically active.
  • Half life62.3 h
  • ExcretionMostly faecal
  • Urinary ExcretionN/A
  • Clerance3.47 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A